Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) was upgraded by stock analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a report issued on Friday.

Separately, Piper Sandler lifted their price objective on Supernus Pharmaceuticals from $33.00 to $38.00 and gave the stock an "overweight" rating in a research report on Wednesday.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN traded down $0.65 on Friday, hitting $34.39. The company's stock had a trading volume of 206,464 shares, compared to its average volume of 417,010. The stock has a 50 day moving average of $31.48 and a 200-day moving average of $30.26. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of 34.05 and a beta of 1.04. Supernus Pharmaceuticals has a 12-month low of $24.95 and a 12-month high of $36.08.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, VP Tami Tillotson Martin sold 5,000 shares of the stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $35.98, for a total transaction of $179,900.00. Following the transaction, the vice president now owns 87,220 shares of the company's stock, valued at approximately $3,138,175.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Supernus Pharmaceuticals news, VP Tami Tillotson Martin sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $35.98, for a total value of $179,900.00. Following the completion of the sale, the vice president now owns 87,220 shares in the company, valued at approximately $3,138,175.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jack A. Khattar sold 39,431 shares of the stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $31.15, for a total transaction of $1,228,275.65. Following the transaction, the chief executive officer now owns 724,978 shares in the company, valued at $22,583,064.70. The disclosure for this sale can be found here. In the last three months, insiders sold 66,733 shares of company stock valued at $2,161,863. Company insiders own 7.99% of the company's stock.

Institutional Trading of Supernus Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Polaris Capital Management LLC increased its position in Supernus Pharmaceuticals by 8,769.9% during the 2nd quarter. Polaris Capital Management LLC now owns 2,918,196 shares of the specialty pharmaceutical company's stock worth $45,611,000 after purchasing an additional 2,885,296 shares in the last quarter. Woodline Partners LP acquired a new stake in shares of Supernus Pharmaceuticals in the first quarter worth $15,689,000. Stephens Investment Management Group LLC raised its stake in shares of Supernus Pharmaceuticals by 27.2% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,577,980 shares of the specialty pharmaceutical company's stock valued at $46,014,000 after acquiring an additional 337,902 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 108.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 550,081 shares of the specialty pharmaceutical company's stock valued at $17,779,000 after acquiring an additional 285,737 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in Supernus Pharmaceuticals during the 2nd quarter worth $7,063,000. 99.81% of the stock is currently owned by institutional investors and hedge funds.

About Supernus Pharmaceuticals

(Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

See Also

• Get a free copy of the StockNews.com research report on Supernus Pharmaceuticals (SUPN)
• Hormel Looks Cheap At These Levels
• Lululemon Set To Soar Into September
• Could Nike Stock be Oversold, but Still Overvalued?
• Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
• Will Royal Caribbean's Broadband Partnership Drive Revenue?

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.